Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort

Fischer, Kathelijn; Carcao, Manuel; Male, Christoph; Ranta, Susanna; Pergantou, Helen; Kenet, Gili; Kartal-Kaess, Mutlu; Königs, Christoph; Carvalho, Manuela; Alvarez, Maria Teresa; Brakenhoff, Timo; Chambost, Hervé; van den Berg, H. Marijke

doi:https://doi.org/10.1016/j.jtha.2022.11.020

Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort

DSpace/Manakin Repository

Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort

Fischer, Kathelijn; Carcao, Manuel; Male, Christoph; Ranta, Susanna; Pergantou, Helen; Kenet, Gili; Kartal-Kaess, Mutlu; Königs, Christoph; Carvalho, Manuela; Alvarez, Maria Teresa; Brakenhoff, Timo; Chambost, Hervé; van den Berg, H. Marijke

(2023) Journal of Thrombosis and Haemostasis, volume 21, issue 3, pp. 700 - 703

(Article)

Download/Full Text

The full text of this publication is not available.

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Hematology

DOI: https://doi.org/10.1016/j.jtha.2022.11.020

ISSN: 1538-7933

Publisher: Wiley-Blackwell

Note: Funding Information: S.R. has received research support from the Childhood Cancer Foundation, Stockholm County Council and PedNet research foundation and consultancy fees from Roche. Funding Information: M.K.K. has received financial support for educational programs from Sobi and consultancy fees from Sobi, Bayer, and Takeda. Funding Information: H.C. has received research support from CSL Behring, LFB, Novo Nordisk, Octapharma, Roche/Chugaï, Shire/Takeda, and Sobi and honoraria from Bayer, LFB, Octa-pharma, Pfizer, Roche, and Sobi.

(Peer reviewed)